EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Association Between Gastric Acid Inhibition and Gastric Cancer Risk After Eradication of Helicobacter pylori

Junya Arai, Yoku Hayakawa, Hiroaki Fujiwara, Masato Kasuga

Journal of Clinical Medicine · 17.11.2026 · 15 (22) · 9000

DOI: 10.3390/jcm15229000 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.11.2026. Verfasst von Junya Arai und 3 weiteren Autor:innen. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daiwa securities Foundation, Kato Memorial Bioscience Foundation, UBE Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Helicobacter pylori eradication has substantially reduced the incidence of gastric cancer and is now a cornerstone of gastric cancer prevention. However, the risk of gastric cancer persists even after successful eradication, and post-eradication gastric cancer has become an increasingly important clinical challenge. Recent epidemiological studies have suggested that long-term use of potent acid suppressants, including proton pump inhibitors (PPIs) and potassium-competitive acid blockers (PCABs), may further increase this residual risk, although findings have been inconsistent across studies. Following eradication, recovery of gastric acid secretion frequently precipitates gastroesophageal reflux symptoms, often leading to prolonged PPI or PCAB therapy, although the overall impact of eradication on the risk of gastroesophageal reflux disease remains uncertain. Some of the large-scale observational studies have demonstrated an association between long-term acid suppressant use and an increased risk of gastric cancer, with evidence of dose- and duration-dependent effects. Although causality has not been established, several biological mechanisms have been proposed. Sustained acid suppression induces hypergastrinemia, which may influence gastric epithelial proliferation and stem/progenitor cell dynamics mainly in the gastric corpus, although its effects appear to vary depending on the gastric region and cellular context. In addition, elevation of gastric pH alters the gastric microbiota, resulting in dysbiosis characterized by enrichment of potentially carcinogenic bacteria, chronic low-grade inflammation, and increased production of genotoxic metabolites. These mechanisms may act synergistically to facilitate gastric carcinogenesis in the post-eradication stomach. Given the accumulating evidence, long-term PPI or PCAB therapy should be prescribed only when clinically indicated, using the lowest effective dose and shortest possible duration. In patients requiring prolonged acid suppression, careful risk assessment and appropriate endoscopic surveillance should be considered. Further prospective studies are needed to clarify the causal relationship between acid suppressants and post-eradication gastric cancer.

Förderung

  • Daiwa securities Foundation
  • Kato Memorial Bioscience Foundation
  • UBE Foundation
  • Mochida Memorial Foundation for Medical and Pharmaceutical Research
  • Takeda Science Foundation
  • Kobayashi Foundation for Cancer Research
  • International Medical Research Foundation
  • Cell Science Research Foundation

Zitieren

APA

Arai, J., Hayakawa, Y., Fujiwara, H., & Kasuga, M. (2026). The Association Between Gastric Acid Inhibition and Gastric Cancer Risk After Eradication of Helicobacter pylori. Journal of Clinical Medicine, 15(22), 9000. https://doi.org/10.3390/jcm15229000

Vancouver

Arai J, Hayakawa Y, Fujiwara H, Kasuga M. The Association Between Gastric Acid Inhibition and Gastric Cancer Risk After Eradication of Helicobacter pylori. Journal of Clinical Medicine. 2026;15(22):9000. doi:10.3390/jcm15229000

BibTeX
@article{Arai2026,
  author = {Arai, Junya and Hayakawa, Yoku and Fujiwara, Hiroaki and Kasuga, Masato},
  title = {The Association Between Gastric Acid Inhibition and Gastric Cancer Risk After Eradication of Helicobacter pylori},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {22},
  pages = {9000},
  doi = {10.3390/jcm15229000}
}
Kostenlos starten →